FUTURA MEDICAL

Stifel is projecting peak worldwide sales of $364 million by 2029 for Futura Medical PLC (AIM:FUM, OTC:FAMDF)'s Eroxon, an innovative gel-based treatment for erectile dysfunction (ED). According to the US investment bank, most of these sales, $223 million, are expected from the US market, with Europe contributing an additional $117 million by 2028. » Mehr auf proactiveinvestors.co.uk

Futura Medical PLC's (AIM:FUM, OTC:FAMDF) clinically proven, topical gel treatment for erectile dysfunction, Eroxon, offers a "significant and still underappreciated opportunity", said Stifel as it initiated coverage on the stock with a 'buy' rating.  As highlighted in today's results, Eroxon last year received marketing approval in the US, EU and UK and is in the early stages of the commercial launch in the UK and EU with its US launch on the horizon, under a partnership with Advil and Sensodyne maker Haleon. » Mehr auf proactiveinvestors.co.uk

Futura Medical PLC (AIM:FUM, OTC:FAMDF) hailed a landmark set of annual results after the successful launch of its Eroxon over-the-counter erectile dysfunction (ED) treatment in the Europe and US, with the company eyeing profitability in the next 12 months. The year saw market approval received from the medical regulator in the US, the largest consumer healthcare markets in the world, plus in several other countries; Haleon secured as US distribution partner with a US$4 million upfront payment to be recognised this year; launches in the UK and Belgium via distribution partner Cooper Consumer Health. » Mehr auf proactiveinvestors.co.uk